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Abstract
Background: Esophageal Squamous Cell Carcinoma (ESCC) is a major subtype of esophageal cancer causing significant
morbility and mortality in Asia. Mechanism of initiation and progression of this disease is unclear. Tumor initiating cells
(TICs) are the subpopulation of cells which have the ability to self-renew, as well as, to drive initiation and progression of
cancer. Increasing evidence has shown that TICs exist in a variety of tumors. However, the identification and characterization
of TICs in esophageal carcinoma has remained elusive.
Methodology/Principal Findings: to identify TICs in ESCC, ESCC cell lines including two primary cells were used for
screening suitable surface marker. Then colony formation assay, drug resistant assay and tumorigenicity assay in immune
deficient mice were used to characterize TICs in ESCC. We found that just the CD44 expression correlated with
tumorigenicity in ESCC cell lines. And then induced differentiation of ESCC cells by all-trans retinoic acid treatment led to
decreased expression of CD44. The FACS isolated cell subpopulations with high CD44 expression showed increased colony
formation and drug resistance in vitro, as well as significantly enhanced tumorigenicity in NOD/SICD mice, as compared to
the low expressing CD44 ESCC cells.
Conclusions/Significance: our study has discovered a novel TIC surface marker, CD44, which can be utilized to enrich
efficiently the TICs in ESCC. These findings will be useful for further studies of these cells and exploring therapeutic
approaches.
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Introduction
Esophageal cancer is one of the most common malignancies
throughout the world, ranking eighth in incidence [1]. It can be
pathologically classified into two major subtypes, Esophageal
Adenocarcinomas (EAC) and Esophageal Squamous Cell Carci-
nomas (ESCC). ESCC especially occurs in developing countries,
and is particularly prevalent in China and other counties in Asia
[1,2]. Although progress has occurred in the diagnosis and
treatment of ESCC, the rate of mortality from this disease has not
improved significantly [3,4]. Lack of advances probably reflects
both not making the diagnosis of the disease until an advanced
stage and a poor understanding of the cellular and molecular
mechanism underlying initiation and progression of ESCC.
Tumor initiating cells (TICs) or cancer stem cells (CSCs) are
defined as a subset of cells in tumors with the capability to self-
renew and differentiate, thus they can either initiate or maintain a
tumor. TICs also exhibit greater resistance to conventional
chemo- and radio-therapies than more differentiated tumor cells
[5]. Therefore, TICs are crucial targets for cancer therapy.
After its first detection in leukemia, TICs have been widely
discovered in solid tumors, including breast, colon, glioma,
prostate, liver and melanoma [6,7,8,9,10,11,12]; however, these
cells have remained elusive in ESCC. In the present study, we
have identified CD44 as a TIC surface marker in ESCC, and
successfully enriched TICs based upon their elevated expression of
CD44. Discovery of this novel TIC marker in ESCC will not only
benefit the investigation of ESCC, but will also provide the
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appropriate target cell for development of effective therapeutic
strategies for ESCC.
Results
Expression of CD44 Correlates with the Tumorigenicity of
ESCC Cell Lines
To identify TICs marker for ESCC, we initially analyzed the
expression pattern of several candidate molecules in the two
primary ESCC cells (ESC1 and ESC2), which were isolated from
ESCC specimens and demonstrated significant difference in
tumorigenicity (Figure 1A). Based on the previous studies of TICs
in other solid carcinomas, the following cell surface proteins were
selected: CD44, CD90, CD133, CD271 and CD326. When ESC1
and ESC2 were analyzed by flow cytometry, only CD44
expression was correlated with tumorigenicity. Although both cell
lines expressed the protein, the expression level of CD44 was much
higher in ESC1, which is the more tumorigenic ESCC cell
(Figure 2A, F and G). Other candidates were either undetectable
in both cells (CD90, CD133 and CD271) or inversely correlated
with tumorigenicity (CD326) (Figure 2B,E).
The differential expression of CD44 on ESC1 and ESC2 cells
prompted us to analyze its expression in Het-1A, an immortalized
esophageal epithelial cell line as well as other ESCC cell lines to
examine further the correlation between expression of CD44 and
tumorigenicity. The expression level of CD44 in Het-1A was
Figure 1. ESC1 is more tumorigenic than ESC2 cells. (A) 56105 of ESC1 or ESC2 cells were s.c. injected into nude mice. 3 weeks after cell
injection, all mice were sacrificed; tumors were isolated and their weights were compared. (B) Tumors derived from both ESC1 and ESC2 were paraffin
embedded. H&E staining was performed on these samples. Representative IHC analyses of p63 (a stemness marker), and CK13 (a differentiation
marker) in ESC1 and ESC2 tumors. Scale bar: 50 micrometer.
doi:10.1371/journal.pone.0021419.g001
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similar to the low expressing ESC2 cells (Figure 2H). Two other
ESCC cell lines, Ec109 and CaES17 were CD44-positive, and
displayed higher expression levels compared to Het-1A and ESC2
cells (Figure 2I, J). Using the comparative level of expression of
CD44 in ESC1 versus Het-1A, we defined CD44 highly expressed
subpopulation cells within the ESC1 line as CD44H (High) cells
and the remainder of the cell population as CD44L (Low)
(Figure 2F).
Expression of CD44 in ESCC Specimens
To investigate whether the potential ESCC TICs with high
expression level of CD44 can be detected in clinical specimens, we
examined CD44 expression in 171 paraffin-embedded ESCC
tissues by IHC staining. In normal esophageal tissues, CD44 was
found to be heterogeneously expressed. Among all the ESCC
specimens, 30% (52/171) were either negative or weakly positive
for CD44, and 70% (119/171) were CD44 strongly positive. The
strongest expression of CD44 was found in the basal layer where
normal esophageal stem cells are localized (Figure 3A, B).
Although no association was found between CD44 expression
and clinicopathological parameters of ESCC patients, except the
degree of cellular differentiation (Table 1), heterogeneous
expression of CD44 was noted in most specimens. Keratin pearls
are structures that occur during terminal differentiation of ESCC
cells; these cells were either weakly positive or negative for CD44
expression (Figure 3C). For most samples, most of the cells were
uniformly strong expressers of CD44; however, a minority of cells
within these samples had low expression of CD44 (Figure 3C, D).
A similar heterogeneity of expression occurred in specimens with
low average weak expression of CD44; nevertheless, some of cells
Figure 2. Expression of cell surface protein on ESCC cells. (A–E) measurement of the expression of CD44 (A), CD90 (B), CD133 (C), CD271 (D)
and CD326 (E) in ESC1 and ESC2 cells by flow cytometry analysis. (F–J) Representative flow cytometry results examining the expression of CD44 in
ESC1 (F), ESC2 (G), Het-1A (H), Ec109 (I) and CaES17 (J) cells. Using the comparative level of expression of CD44 in ESC1 versus Het-1A, we defined
CD44 highly expressed subpopulation cells within the ESC1 line as CD44H (High) cells, and the remainder of the cell population as CD44L (Low) (F).
ESC1 Iso (red line): ESC1 cells stained with isotype control antibody; ESC1 Protein (green line): ESC1 cells stained with candidate surface protein
antibody; ESC2 Iso (blue line): ESC2 cells stained with isotype control antibody; ESC2 Protein (brown line): ESC2 cells stained with candidate surface
protein antibody; FITC: fluorescein isothiocyanate; APC: allophycocyanin; SSC: side scatter.
doi:10.1371/journal.pone.0021419.g002
Figure 3. Expression of CD44 in ESCC specimens. (A) Representative IHC analyses of CD44 in normal esophageal tissues. (B) Magnification of (A)
demonstrated that the expression of CD44 was in the basal layer (indicated by arrow). (C–F) Representative IHC analyses of CD44 in ESCC tissues. (C–
D) showed specimens with strong expression of CD44 and (E–F) showed cases with weak expression of CD44. * indicated keratin pearl, a structure
which represents terminal differentiation of the cancer cells; Letter ‘‘L’’, cells exhibiting lower expression level of CD44 in (C–D); letter ‘‘H’’, cells
exhibiting higher expression of CD44 in (E–F). Scale bar: 50 micrometer.
doi:10.1371/journal.pone.0021419.g003
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strongly expressed CD44 (Figure 3E, F). These results suggest that
potential ESCC TICs with high expression level of CD44 may
exist in clinical ESCC samples.
Inducing ESCC Cells to Differentiation Reduces their
Expression of CD44
Beside greater tumorigenicity, tumors generated from ESC1
cells exhibited less differentiation than those derived from ESC2
cells, as shown by light microscopy using H&E staining (Figure 1B).
Meanwhile, the expression of p63, a marker of normal esophageal
stem cells, was strongly expressed in ESC1 tumors (Figure 1B).
The expression of CK13, a marker of differentiation esophageal
epithelium, was down expressed in ESC1 tumors (Figure 1B).
These results prompted us to analyze whether inducing the
differentiation of ESCC cells can decrease the expression of CD44.
After ESC1 or CaES17 cells were treated with 20 mM all-trans
retinoic acid (ATRA), a widely used differentiation inducer,
significant morphological alterations were observed. These ESC1
or CaES17 cells became larger and flatter after ATRA treatment
(Figure 4A and Figure S1A). To verify the efficiency of ATRA-
induced differentiation, we examined the mRNA expression of
stemness and differentiation markers of esophageal epithelium
cells by real-time PCR. Compared to controls, ATRA treatment
significantly reduced the expression of p63 (stemness marker),
while increasing the expression of CK4 (differentiation marker)
(Figure 4B, C and Figure S1B, C). Also, the expression of CD44 at
both the mRNA and protein level was significantly downregulated
in these ATRA-induced differentiated ESCC cells (Figure 4D, E
and Figure S1D, E).
CD44H Enrich TICs in ESCC Cell Lines
To determine whether higher expression of CD44 can enrich
TICs in ESCC cells, CD44H and CD44L cells were sorted from
ESC1 by FACS and injected subcutaneously in NOD/SCID mice
at different dosages. At 16102 cells, three out of 5 mice displayed
visible tumors in the CD44H group at 5 weeks after injection.
However, only one out of 5 mice at this cell dose generated visible
tumors in the CD44L group (Figure 5A, D). Although all mice
injected with higher cell doses of CD44H and CD44L cells (16103
and 16104) finally formed visible tumors, those from CD44H cells
as compared to CD44L displayed a shorter latency for tumor
development, and their tumors were a significantly larger
(Figure 5B, C and E, F). A similar result was observed with
Ec109 cells; 16102 sorted CD44H cells produced tumors in four
of 5 injected mice, compared to two of 5 tumors in CD44L cell
group (Table S3).
As previously reported, TICs reproduce tumors with similar
characteristics as the primary ones. All the tumors derived from
CD44H and unsorted ESC1 cells were pathologically analyzed by
H&E staining, and no noticeable differences were observed (Figure
S2A, B). Also, the percent and level of expression of CD44 within
the tumors derived from either CD44H cells or parental ESC1
cells were similar as determined by flow cytometry (Figure S2D).
We further isolated CD44H and CD44L cells from these first
generate xenografts derived from CD44H cells to analyze their
ability to reproduce serially transplantable tumors. As well as in
the first generate xenografts, CD44H cells also shown stronger
tumorigenicity in second generate xenografts (Figure S3).
Other than tumorigenicity, sphere formation and side popula-
tion (SP) cells are considered as two important characteristics of
TICs. However, we could not detect sphere formation in any of
ESCC cells used in this study, even when the cells were cultured in
sphere culture medium (DMEM/F12+B27+EGF+bFGF+Insulin)
(data not show). SP cells were detected in CaES17 cells, but not in
ESC1, ESC2 and Ec109 cells (data not show). So, no correlation
was noted between degree of SP and tumorigenicity of the cell
population.
Another characteristic of TICs is resistance to chemo- and
radio-therapy. We treated ESC1 and Ec109 cells with traditional
chemotherapeutic drugs, DDP (cis-Diammineplatinum(II) dichlo-
ride) and 5-Fu (5-Fluorouracil), and then analyzed the expression
of CD44 by flow cytometry. DDP and 5-Fu treatment dramat-
ically reduced the cell proportions at G2/M phase and induced
cell death of ESC1 and Ec109 cells (Figure 6A, D and Table S4).
In contrast, these same treatments markedly increased the percent
of CD44H cells in both cell lines (Figure 6B, C and E, F),
indicating that the CD44H population had a greater drug
resistance to ‘‘cell- kill’’ by these two commonly used chemo-
therapeutic drugs. To explore the mechanism, we analyzed the
expression of some drug resistance related gene in both CD44H
and CD44L cells. Two well known genes, ABCG2 and ABCA5
that involved in drug resistance in many types of tumor were
overexpressed in CD44H cells (Figure S4).
The clonogenic capacity of CD44H and CD44L cells from
ESC1 and CaES17 was also analyzed. Consistent with the
previous reports concerning TICs in other tumors [13,14],
CD44H cells formed more and larger colonies than CD44L cells
(Figure 5G, H). These may partially due to the overexpression of
CDC2 in CD44H cells (Figure S4).
Discussion
Although TICs have been widely reported in other tumors, few
studies have focused on ESCC. SP cells have been found in several
Table 1. Relationship between clinicopathological features
and CD44 expression.
Parameters CD44 expression level p-value*
Negative or low High
Age 0.733
,55 18 (29%) 45 (71%)
$55 34 (31%) 74 (69%)
Gender 0.338
Male 36 (28%) 92 (72%)
Female 16 (37%) 27 (63%)
Regional lymph nodes 1.000
N0 28 (31%) 63 (69%)
N1 24 (30%) 56 (70%)
TNM staging 1.000
I/IIa 28 (31%) 63 (69%)
IIb/III/IV 24 (30%) 56 (70%)
Grade of differentiation 0.001
Well 6 (13%) 42 (87%)
Moderate 35 (34%) 68 (66%)
Poor 11 (55%) 9 (45%)
The IHC procedure was done as described previously [40]. The intensity of
positive staining for CD44 was evaluated as negative, weak staining, moderate
staining and strong staining. For chi-square test, negative, weak and moderate
staining for CD44 were considered as CD44-negative or -low expression, and
strong staining of CD44 was considered as CD44-high.p,0.05 was considered
significant. N0: without lymph node metastasis; N1: with lymph node
metastasis; TNM: tumor, node, metastasis.
doi:10.1371/journal.pone.0021419.t001
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ESCC cell lines by staining with Hochest 33342, and these cells
demonstrated greater tumorigenicity than non-SP cells [15].
p75NTR (CD271), a stem cell marker for normal human
esophagus, was examined in ESCC cell lines. Previous study
showed that p75NTR expressing ESCC cells were resistant to
DDP and expressed higher levels of stem cell-associated genes
[16]. These results suggested the existence of TICs in ESCC, but
their identification and characterization remained elusive.
Using a similar strategy employed for identification of TICs
markers in other tumors [17], we detected a group of candidate
markers in two primary ESCC cells isolated from clinical specimens,
and only CD44 expression correlated with tumorigenicity of these
cells. Analysis of CD44 expression in an established immortalized
esophageal epithelial cell line and ESCC cell lines further verified this
correlation. CD44 is a widely used marker for TICs studies, especially
in gastrointestinal tumors such as gastric and colon cancer
[8,18,19,20]. In these previous studies, CD44 positive TICs were
enriched and characterized. However, cancer cells which highly
expressed CD44 were also reported to be enriched for TICs in several
other types of human cancers. For example, a subpopulation of breast
cancer cells which highly expressed CD44, were characterized as
TICs [21,22]. Although we found the expression of CD44 correlated
with tumorigenicity of ESCC cells, our flow cytometry results showed
that nearly all the cells expressed varying intensities of CD44,
including the immortalized esophageal epithelial cell line Het-1A.
Therefore, we defined CD44H and CD44L samples based on the
expression of CD44 in Het-1A (immortalized esophageal epithelial
cell) and a low tumorigenic ESCC cell line (ESC2).
The heterogeneous expression of CD44 was previously reported
in normal esophageal tissues [23,24]. The strongest expression of
CD44 occurred in the basal layer where normal esophageal stem
cells are localized. Consistent with these results, we also found
CD44 was positive in normal esophageal epithelial cells, and the
strongest staining occurred in the basal layer. Overexpression of
CD44 in ESCC has been noted previous, but a correlation
between level of expression and prognosis was unclear
[24,25,26,27]. Although high expression of CD44v6, a variant of
CD44, has been reported to correlate with invasive and metastatic
ability of ESCC, we did not find a significant association between
CD44 expression and clinicopathological indices in this study
[26,27]. However, we detected heterogeneous expression of CD44
in individual ESCC specimen. These results indicate that in most
Figure 4. Differentiation of ESC1 downregulated expression of CD44. (A) Morphology of ESC1 cells treated with 20 mM ATRA for 5 days. (B–
C) Real-time RT PCR of ATRA treated ESC1: p63 mRNA, an esophageal stemness marker (B); CK4, a differentiation marker (C). (D–E) Real-time RT PCR
(D) and western blot (E) analysis of CD44 expression in ATRA-induced, differentiated ESC1 cells (20 mM, 5 days). Real-time RT PCR experiments were
performed in triplicate and results were shown as mean 6 SD. NC: blank control; DMSO: DMSO deluent treated cells; ATRA: ATRA treated cells; Scale
bar: 50 micrometer.
doi:10.1371/journal.pone.0021419.g004
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ESCC samples, cancer cells can be classified into different
subpopulations based upon CD44 intensity of expression. Here,
high levels of CD44 may be a feature not only of normal
esophageal stem cells but also of TICs in ESCC.
The most important measure of TICs is their ability to initiate
tumors in immunodeficient mice [28]. Therefore, we isolated
CD44H and CD44L subpopulations from ESCC cells and
injected them into NOD/SICD mice at serial dosages. A
Figure 5. CD44H subpopulation was more tumorigenic than CD44L cells. (A–C) Tumorigenicity of 16102 (A), 16103 (B) or 16104 (C) sorted
CD44H and CD44L ESC1 cells in NOD/SCID mice. (D) Representative NOD/SCID mice with subcutaneous tumors from either CD44H (circle dash line) or
CD44L (no tumor formed) ESC1 cells at the dosage of 16102. (E–F) Average tumor weight of CD44H tumors and CD44L tumors at the dosage of either
16103 (E upper panel) or 16104 (F upper panel). Representative subcutaneous tumors derived from CD44H or CD44L ESC1 cells at the dosage of
either 16103 (E lower panel) or 16104 (F lower panel). Data are generated from 5 mice in each group. (G) Representative photographs of the plates
containing colonies derived from either 2000 CD44H or CD44L ESC1 or CaES17 cells. (H) Quantification of (G) by Crystal Violet staining. Colony
formation experiments were performed in triplicate (mean 6 SD).
doi:10.1371/journal.pone.0021419.g005
Esophageal Tumor Initiating Cells and CD44
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Figure 6. Chemotherapeutic drugs induced cell death in ESC1 and Ec109 cells and enriched for a CD44H population of cells. (A)
Morphology of ESC1 cells treated with either 12.5 mg/ml DDP (cis-Diammineplatinum(II) dichloride, right upper panel) or 1.25 mg/ml 5-FU (5-
Fluorouracil, right lower panel) for 2 days. (B–C) Representative flow cytometry analyses of CD44 expression in ESC1 cells after either DDP (B) or 5-FU
(C) treatment. (D) Morphology of Ec109 cells treated with either 50 mg/ml DDP (right upper panel) or 2 mg/ml 5-FU (right lower panel) for 2 days. (E–F)
Representative flow cytometry analyses of CD44 expression in Ec109 cells after either DDP (E) or 5-FU (F) treatment. Iso: isotype control; NC: blank
control; DMSO: DMSO diluents treated cells; DDP: DDP treated cells; 5-FU: 5-FU treated cells; Scale bar: 50 micrometer.
doi:10.1371/journal.pone.0021419.g006
Esophageal Tumor Initiating Cells and CD44
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significant increase of tumorigenicity paralleled elevated expres-
sion of CD44 (CD44H), especially when low cell inoculums (100
cells) were injected. Consistent with these results, CD44H cells also
produced more and larger colonies than CD44L cells in colony
formation assays. Furthermore, the CD44H cells were more
resistant to cell kill by traditional chemotherapeutic drugs, as
shown by DDP and 5-FU significantly enriching the CD44H
population of both ESC1 and Ec109 cells. Although sphere culture
and SP cell analysis have been used to isolate or identify TICs in
ESCC cell lines, neither method enriched TICs from cell lines
examined in the present study. Sphere and SP cells have been
detected in a limited number of cell lines. Also in some reports, SP
cells did not show characteristics of TICs when compared with
non-SP cells [29,30]. Taken together, our results demonstrate that
the CD44H subpopulation of cells represents the enriched TICs in
ESCC cells.
A major purpose of identifying and characterizing TICs is to
develop more effective strategies to eliminate cancers by targeting
TICs. An attractive procedure is inducing differentiation of TICs;
this approach can be called differentiation therapy. The well
known use of ATRA in acute promyelocytic leukemia is a vivid
illustration of this approach [31,32,33]. ATRA also is a widely
used differentiation-inducer of stem cells [34,35]. Previous data
have shown that ATRA can induce differentiation of normal
esophageal stem cells [36]. At the same time, ATRA can inhibit
ESCC cell proliferation [37,38,39]. We found that ATRA can
induce differentiation of ESC1 cells and dramatically downregu-
late expression of both mRNA and protein levels of CD44. These
results suggest that ATRA can induce differentiation of TICs of
ESCC suggesting a potential application of ATRA differentiation
therapy for ESCC.
Although we show that isolating CD44H expressing cells can
enrich for TICs in ESCC cells, function of this protein in TICs of
ESCC is still unknown and deserves further study. Additionally,
the fact that isolation of CD44H cells can enrich but cannot
exclusively purify TICs in ESCC, suggests addition studies are
needed to identify companion markers of TICs in ESCC.
Materials and Methods
Cell lines and Reagents
Two primary ESCC cell lines, ESC1 and ESC2, were recently
derived from two ESCC patients treated at Zhongshan Hospital of
Fudan University (Shanghai, China), after their written informed
consent. Briefly, fresh cancer tissues were minced to 1 mm3 pieces
and incubated in D-Hanks containing collagenase type I (1 mg/
ml; Worthington Biomedical Corporation ) at 37uC for 10 to
12 hours. The digested ESCC tissue was incubated in ACK lysis
buffer (TIANGEN) to remove red blood cells. After washing three
times with D-Hanks, single cells were cultured in RPMI1640
supplemented with 10% fetal bovine serum, 10 units/ml
penicillin/streptomycin, at 37uC in a humidified atmosphere
containing 5% CO2. To enrich for the cancer cells, the adherent
cells were digested with 0.05% trypsin containing 0.53 mM EDTA
at 37uC for 30 seconds, resulting in the differential detachment of
the fibroblasts with most cancer cells still remaining adherent.
HET-1A, an immortalized human esophageal epithelial cell line
(ATCC) was cultured in Airway epithelial cell culture medium
with supplements (PromoCell) with 10 units/ml penicillin/
streptomycin. The other two ESCC cell lines, CaES17 and
Ec109, were cultured similarly as ESC1 and ESC2.
Fluorescein isothiocyanate (FITC) conjugated CD44 and CD90
antibodies were purchased from BD Biosciences. FITC conjugated
CD326 (EpCAM) and CD271 (p75NTR), and allophycocyanin
(APC) conjugated CD133 antibodies were from Miltenyi Biotec.
All comparable isotype control antibodies were from eBioscience.
CD44 antibody used for Western Blot was purchased from Cell
Signaling Technology. Actin antibody was from Santa Cruz
Biotechnology. All-Trans Retinoic Acid (ATRA), cis-Diammine-
platinum(II) dichloride (DPP) and 5-Fluorouracil (5-FU) were from
Sigma-Aldrich.
Flow cytometry and Fluorescence Activated Cell Sorting
(FACS)
Cultured or treated cells were dissociated from culture plates by
using trypsin-EDTA and centrifuged. Single cells were resus-
pended with D-Hanks containing 2% FBS, fluorochrome-
conjugated antibody or compared isotype control antibody were
added and the cells were incubated on ice for 30 minutes. After
washing three times with D-Hanks containing 2% FBS, cells were
resuspended with D-Hanks containing 2% FBS and 1 ug/ml
propidium iodide (PI). Samples were analyzed or sorted by BD
FACS Aria (BD Biosciences).
Immunohistochemistry (IHC)
Paraffin embedded ESCC and normal mucosa specimens were
obtained from 171 patients who were treated in the Department of
Cardiothoracic Surgery of the First Affiliated Hospital of Shantou
University Medical College and who provided written informed
consent (Table S1). Immunohistochemistry was done as described
previously [40]. The intensity of positive staining for CD44 was
evaluated as negative, weak staining, moderate staining and strong
staining. For statistical analysis, negative, weak and moderate
staining for CD44 were considered as CD44-negative or -low
expression, and strong staining of CD44 was considered as CD44-
high expression.
In vivo tumorigenicity assay
Six-week-old male nude mice or nonobese diabetic-severe
combined immune deficient (NOD/SCID) mice were used in this
study. All animal experiments were done in agreement with SIBS
Guide for the Care and Use of Laboratory Animals and approved
by Animal Care and Use Committee, Shanghai Institutes for
Biological Sciences. For detecting tumor initiation ability, FACS
sorted subsets of cells from ESC1 or Ec109 were mixed with
matrigel (2:1, volume/volume) and s.c. injected on both flanks of
NOD/SCID mice. Tumor growth was monitored every three or
four days. For other assays, cancer cells were injected into nude
mice as described.
Colony formation assay
2000 cells from both subsets of ESC1 after FACS were seeded in
6-well plates. After 10 days culture, cells were stained with Crystal
Violet (0.5% Crystal Violet dissolved in 20% methanol). For cell
number quantification, the stained cells were solubilized in 1%
SDS and the absorbance at 600 nm was taken by a microplate
reader.
RNA isolation and Real-time PCR
Total RNA was extracted from cells using Trizol, according to
the manufacturer’s instructions. 2 mg RNA from each sample was
processed directly to cDNA using the reverse transcription kit
(Promega, Madison, WI). Amplification was done in a 15 mL
reaction system with 0.2 mL SYBR Green. All of the reactions
were performed in triplicate in an iCycler iQ System (Bio-Rad).
Primers used in this study were designed by software
PRIMER5. The sequence of each primer is listed in Table S2.
Esophageal Tumor Initiating Cells and CD44
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Western blot
Proteins were extracted from cells using RIPA buffer, and
protein concentrations were quantified using Bradford reagent
(Sigma) according to the manufacturer’s instructions. Samples
with equal amount of proteins were separated on 10% SDS-
PAGE, and then transferred to Immobilon transfer membrane
(Millipore, Bedford, MA) and immunoblotted with specific
antibodies. All immunoblots were visualized by enhanced
chemiluminescene.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 for windows.
Statistically significant differences were determined by Student’s
test, one-way ANOVA and chi-square test, where appropriate,
and defined as P,0.05.
Supporting Information
Figure S1 Differentiation of CaES17 downregulated
expression of CD44. (A) Morphology of CaES17 cells treated
with 20 mM ATRA for 5 days. (B–C) Real-time RT PCR of
ATRA treated CaES17: p63 mRNA, an esophageal stemness
marker (B); CK4, a differentiation marker (C). (D–E) Real-time
RT PCR (D) and western blot (E) analysis of CD44 expression in
ATRA-induced, differentiated CaES17 cells (20 mM, 5 days).
Real-time RT PCR experiments were performed in triplicate and
results were shown as mean 6 SD. NC: blank control; DMSO:
DMSO deluent treated cells; ATRA: ATRA treated cells; Scale
bar: 50 micrometer.
(TIF)
Figure S2 CD44H cells formed similar tumors as
parent cells. (A–C) Representative H&E staining analyses of
tumors derived from ESC1 CD44H and CD44L subpopulation
cells and unsorted ESC1 cells. (D) Representative flow cytometry
analyses of CD44 expression in ESC1 cells and tumors derived
from ESC1 CD44H and CD44L subpopulation cells. ESC1:
tumors derived from ESC1 cells; H-P1: tumors derived from
ESC1 CD44H subpopulation cells; L-P1: tumors derived from
ESC1 CD44L subpopulation cells; ESC1 Iso (red line): ESC1
tumor cells stained with isotype control antibody; ESC1 CD44
(green line): ESC1 tumor cells stained with CD44 antibody; H-P1
Iso (blue line): H-P1 tumor cells stained with isotype control
antibody; H-P1 CD44 (brown line): H-P1 tumor cells stained with
CD44 antibody; L-P1 Iso (pink line): L-P1 tumor cells stained with
isotype control antibody; L-P1 CD44 (light blue line): L-P1 tumor
cells stained with CD44 antibody;Scale bar: 50 micrometer.
(TIF)
Figure S3 CD44H cells can reproduce serially trans-
plantable tumors. (A) Tumorigenicity of sorted CD44H and
CD44L ESC1 cells in nude mice. (B) Tumorigenicity of sorted
CD44H and CD44L ESC1 cells from the first generation tumors
in nude mice. 16104 cells had been injected in both assays.
(TIF)
Figure S4 Genes involved in drug resistance and cell
growth were upregulsted in CD44H cells. ABCG2, ABCB5
and CDC2 expression in CD44H and CD44L ESC1 cells were
analyzed by Real-time RT PCR. Experiments were performed in
triplicate and results were shown as mean 6 SD.
(TIF)
Table S1 Clinicopathologic features of patients with
ESCC.
(DOC)
Table S2 Primers used for Real-Time PCR.
(DOC)
Table S3 Tumor initiation ability of CD44H and CD44L
cells isolated from Ec109 cells.
(DOC)
Table S4 Cell death and cell cycle arrest of ESC1 and
Ec109 after drug treatment.
(DOC)
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